Key Points
- iRadimed CEO Roger Susi sold 2,500 shares on June 1 for about $226,500 at an average price of $90.60. The trade was made under a pre-arranged Rule 10b5-1 plan, and he still owns 2,162,500 shares.
- The company recently reported better-than-expected quarterly results, posting EPS of $0.49 versus the $0.46 consensus and revenue of $21.98 million versus $21.32 million expected. iRadimed also raised guidance, including FY 2026 EPS guidance of 2.060 to 2.210.
- iRadimed paid a quarterly dividend of $0.20 per share, equal to an annualized yield of about 0.9%. Analysts currently maintain a Buy consensus with a $120 price target.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 2,500 shares of the company's stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the sale, the chief executive officer owned 2,162,500 shares in the company, valued at approximately $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed Price Performance
Shares of IRMD stock opened at $89.86 on Wednesday. iRadimed Corporation has a 1 year low of $55.11 and a 1 year high of $107.90. The stock's 50 day simple moving average is $91.71 and its two-hundred day simple moving average is $95.47. The company has a market cap of $1.15 billion, a PE ratio of 49.10 and a beta of 0.91.
iRadimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities research analysts expect that iRadimed Corporation will post 1.52 EPS for the current year.
iRadimed Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed's dividend payout ratio is currently 43.72%.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP bought a new position in iRadimed in the third quarter worth approximately $40,000. Farther Finance Advisors LLC grew its stake in iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 397 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 495 shares in the last quarter. CWM LLC grew its stake in iRadimed by 19.5% in the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider's stock worth $64,000 after purchasing an additional 107 shares in the last quarter. Finally, State of Wyoming bought a new position in iRadimed in the third quarter worth approximately $72,000. Institutional investors own 92.34% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on IRMD. Freedom Capital raised iRadimed to a "strong-buy" rating in a research note on Thursday, April 2nd. Roth Mkm reaffirmed a "buy" rating and set a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Weiss Ratings cut iRadimed from a "buy (b)" rating to a "buy (b-)" rating in a research note on Wednesday, May 20th. Finally, Lake Street Capital reaffirmed a "buy" rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $120.00.
Get Our Latest Research Report on iRadimed
iRadimed Company Profile
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
